ViiV ownership shifts as Pfizer sells its stake Pfizer will relinquish its stake in HIV firm ViiV in a deal valued at $2.1bn that ramps up Shionogi's interest and simplifies its share structure

#ViiV #Pfizer #ViiVHealthcare #Shionogi #HIV #GSK #strategicpartnership #jointventure #HIVtherapies #GileadSciences #HIVtreatment #antiretroviraltherapy #longeractinginjectableregimens #HIVpreexposureprophylaxis #PrEP #preexposureprophylaxis #Apretude #cabotegravir #lenacapavir
zurl.co/khJ6D